Actemra

(Tocilizumab)

ApprovedMonoclonal antibody

Tocilizumab is used to treat rheumatoid arthritis and other inflammatory conditions by reducing inflammation in the body. It is also used to treat severe COVID-19 in hospitalized patients.[2] Actemra is currently approved and in use across 72 indications[4].[1]

Actemra is one of 1182 small molecule programs targeting Leukemia. It is currently in Approved.

Indications

449

Total Trials

Active Trials

1,181

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

LeukemiaRecruiting

COVID-19Unknown status

UveitisTerminated

LymphomaRecruiting

NecrosisActive, not recruiting

KidneyActive, not recruiting

Systemic SclerodermaUnknown

Nasopharyngeal CarcinomaActive, not recruiting

ObesityActive, not recruiting

Temporal ArteritisUnknown

LeukemiaPhase 1

Recruiting

COVID-19Approved

Unknown status

UveitisPhase 2

Terminated

LymphomaPhase 3

Recruiting

NecrosisPreclinical

Active, not recruiting

KidneyPreclinical

Active, not recruiting

Systemic SclerodermaPreclinical

Unknown

Nasopharyngeal CarcinomaPreclinical

Active, not recruiting

ObesityPreclinical

Active, not recruiting

Temporal ArteritisPreclinical

Unknown

Showing 10 of 72 indications

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Actemra

CCelltrion

Approved

2 2

Monalizumab

AstraZeneca

Phase 3

5 3

Gotistobart

OOncoC4, Inc.

Phase 3

1 4

Remeron

OOrganon and Co

Preclinical

1 5

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—6

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—7

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

1 8

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

1 10

PD-1 Inhibitors

BBioNTech US Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/ARecruiting

Tocilizumab

NCT07377058

Post-ApprovalRecruiting

Study completion

NCT06251076

Q1 2027

Phase 1Recruiting

Metastatic Cancer

NCT06016179

Phase 2Recruiting

Dexamethasone

NCT07334379

Q2 2027

Phase 1Active, not recruiting

Tocilizumab

NCT03970226

N/ARecruiting

Tocilizumab

NCT07006532

Clinical

Trials by Indication[1]

Rheumatoid Arthritis85 trials

To Evaluate 1 Year Extension Study of the Efficacy and Safety of Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis

Completed·JJW Pharmaceutical·Phase 3·NCT01256736·89 enrolled

Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)

Completed· Regeneron logo

Regeneron·Phase 1·NCT02097524·105 enrolled

An Observational Study to Evaluate the Clinical Effectiveness, Quality of Life, Safety and Tolerability of Tocilizumab (TCZ) in Patients With Rheumatoid Arthritis (RA) in Daily Clinical Practice

Completed· Roche logo

Roche··NCT02552940·140 enrolled

Show 82 more trials

Uncontrolled Study to Evaluate Efficacy of Tocilizumab in Patients With Moderate or Severe Rheumatoid Arthritis

Unknown status·SSpanish Foundation of Rheumatology·Phase 4·NCT02087696·122 enrolled

A Study of the Effect of Tocilizumab on Markers of Atherogenic Risk in Patients With Moderate to Severe Rheumatoid Arthritis

Completed· Roche logo

Roche·Phase 3·NCT00535782·132 enrolled

A Long-Term Extension Study of WA22763 and NA25220 of Subcutaneous RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis

Completed· Roche logo

Roche·Phase 3·NCT01772316·47 enrolled

A Study of Tocilizumab (RoActemra/Actemra) Versus Adalimumab in Patients With Rheumatoid Arthritis

Completed· Roche logo

Roche·Phase 4·NCT01119859·326 enrolled

Effects of Antirheumatic Treatment on Levels of Survivin in Rheumatoid Arthritis Patients

Unknown status·VVastra Gotaland Region··NCT03440892·2,500 enrolled

A Study of Tocilizumab in Combination With DMARD Therapy in Patients With Active Rheumatoid Arthritis.

Completed· Roche logo

Roche·Phase 3·NCT00773461·209 enrolled

A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor

Terminated· Roche logo

Roche·Phase 4·NCT01283971·96 enrolled

A Study to Assess the Effect of Tocilizumab + DMARD Therapy on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis

Completed· Roche logo

Roche·Phase 3·NCT00106574·1,220 enrolled

A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment

Completed· Roche logo

Roche·Phase 3·NCT00810199·556 enrolled

A Study of RoActemra/Actemra (Tocilizumab) With or Without Methotrexate in Patients With Mild to Moderate Rheumatoid Arthritis With an Inadequate Response to Methotrexate

Completed· Roche logo

Roche·Phase 3·NCT01587989·77 enrolled

Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate

Unknown status·AAtsushi Kawakami·Phase 3·NCT05090410·400 enrolled

A Study of RoActemra/Actemra (Tocilizumab) Given Subcutaneously in Combination With Traditional DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis

Completed· Roche logo

Roche·Phase 3·NCT01232569·656 enrolled

A Study of RoActemra/Actemra (Tocilizumab) Plus DMARDs in Patients With Rheumatoid Arthritis

Completed· Roche logo

Roche·Phase 3·NCT01214733·30 enrolled

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Completed· Roche logo

Roche·Phase 3·NCT01332994·519 enrolled

A Study of the Effects of RoActemra/Actemra (Tocilizumab) on Neutrophils in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic and/or Non-biologic DMARDs.

Completed· Roche logo

Roche·Phase 4·NCT01195272·21 enrolled

A Study of Tocilizumab With or Without Methotrexate in Patients With Rheumatoid Arthritis.

Completed· Roche logo

Roche·Phase 4·NCT01010503·32 enrolled

A Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs or Anti-TNF

Completed· Roche logo

Roche·Phase 3·NCT01326962·28 enrolled

A Long-Term Safety Extension Study of WA19926 in Participants With Rheumatoid Arthritis

Completed· Roche logo

Roche·Phase 3·NCT01649804·12 enrolled

A Study of RoActemra/Actemra (Tocilizumab) in Adult Patients With Rheumatoid Arthritis (SVOBODA Programme)

Completed· Roche logo

Roche·Phase 4·NCT02010216·23 enrolled

A Study to Assess the Safety and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis

Completed· Roche logo

Roche·Phase 3·NCT00109408·673 enrolled

A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis Currently on Methotrexate Therapy

Completed· Roche logo

Roche·Phase 3·NCT00106522·499 enrolled

Effects of Interleukin-6 Inhibition on Vascular, Endothelial and Left Ventricular Function in Rheumatoid Arthritis

Unknown status·UUniversity of Athens··NCT03288584·60 enrolled

A Study of Tocilizumab and Methotrexate in Combination or as Monotherapy in Treatment-Naïve Patients With Early Rheumatoid Arthritis

Completed· Roche logo

Roche·Phase 3·NCT01034137·317 enrolled

A Study of Combination Treatment With MabThera (Rituximab) and RoActemra (Tocilizumab) Versus RoActemra in Patients With Rheumatoid Arthritis With an Incomplete Response to Methotrexate

Terminated· Roche logo

Roche·Phase 2·NCT00845832·24 enrolled

A Study of RoActemra/Actemra (Tocilizumab) in Combination With DMARDs Versus Current Best Practice DMARD Therapy in Patients With Rheumatoid Arthritis

Terminated· Roche logo

Roche·Phase 4·NCT01251120·2 enrolled

A Study of Subcutaneously Administered Tocilizumab in Patients With Rheumatoid Arthritis

Completed· Roche logo

Roche·Phase 1·NCT00965653·29 enrolled

A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis

Completed· Roche logo

Roche·Phase 3·NCT00106548·623 enrolled

A Study of Tocilizumab Plus Non-biological DMARD in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Non-biological DMARDs

Completed· Roche logo

Roche·Phase 4·NCT01034397·54 enrolled

Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy

Completed· UCB logo

UCB·Phase 2·NCT01242488·221 enrolled

A Study to Assess the Effect of Tocilizumab + Methotrexate on Prevention of Structural Joint Damage in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA)

Completed· Roche logo

Roche·Phase 3·NCT00106535·1,196 enrolled

TORPEDO Study: A Study on Rapid Effect of Tocilizumab in Patients With Rheumatoid Arthritis With an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs) or Anti-TNF

Completed· Roche logo

Roche·Phase 3·NCT00977106·103 enrolled

A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate Versus RoActemra/Actemra Monotherapy in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Completed· Roche logo

Roche·Phase 4·NCT01399697·261 enrolled

A Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis

Completed· Roche logo

Roche·Phase 3·NCT01245439·65 enrolled

A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Non-biologic DMARDs

Completed· Roche logo

Roche·Phase 3·NCT01353859·39 enrolled

A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Early Moderate to Severe Rheumatoid Arthritis Who Completed Study WA19926

Completed· Roche logo

Roche·Phase 3·NCT01730456·13 enrolled

An Open-label Study With Tocilizumab in Patients With Rheumatoid Arthritis in a Local Environment

Completed· Roche logo

Roche·Phase 3·NCT01254331·51 enrolled

A Study of Subcutaneous RoActemra/Actemra (Tocilizumab) as Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Patients With Active Rheumatoid Arthritis

Completed· Roche logo

Roche·Phase 3·NCT01995201·401 enrolled

A Study of Tocilizumab Added to DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to DMARDs.

Completed· Roche logo

Roche·Phase 4·NCT00996203·201 enrolled

Filling Bone Erosions: a Longitudinal Multicentric HR-pQCT Study of Subcutaneous Tocilizumab in Rheumatoid Arthritis

Completed·—·Phase 4·NCT02765074·60 enrolled

A Study to Assess the Effect of Tocilizumab Plus Methotrexate on Safety and Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis

Completed· Roche logo

Roche·Phase 3·NCT00754572·418 enrolled

A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs)

Completed· Roche logo

Roche·Phase 3·NCT00891020·886 enrolled

A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs (REMISSION)

Completed· Roche logo

Roche·Phase 3·NCT01610791·121 enrolled

A Study of Tocilizumab as Monotherapy or in Combination With DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis

Completed· Roche logo

Roche·Phase 4·NCT01089023·95 enrolled

A Study to Assess the Effect of Tocilizumab on Signs and Symptoms in Patients With Rheumatoid Arthritis

Completed· Roche logo

Roche·Phase 3·NCT00848120·29 enrolled

A Study With Tocilizumab [RoActemra/Actemra] Monotherapy or in Combination With Methotrexate in Patients With Rheumatoid Arthritis (PICTURE)

Completed· Roche logo

Roche·Phase 3·NCT01063062·107 enrolled

Ultrasound as Imaging Biomarker of Early Response to Tocilizumab and Methotrexate in Very Early Rheumatoid Arthritis

Unknown status·MMaria Stoenoiu·Phase 3·NCT02837146·45 enrolled

A Drug Interaction Study Between Tocilizumab, Methotrexate and Simvastatin on Patients With Rheumatoid Arthritis.

Completed· Roche logo

Roche·Phase 1·NCT00365001·23 enrolled

A Study of Tocilizumab + DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis

Completed· Roche logo

Roche·Phase 3·NCT00951275·105 enrolled

A Study of Glucocorticoid Use to Evaluate Systematic Methylprednisolone Reduction in Patients With Rheumatoid Arthritis on Background RoActemra/Actemra (Tocilizumab) (ACT-ALONE)

Completed· Roche logo

Roche·Phase 4·NCT01219933·68 enrolled

A Study of Tocilizumab in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic DMARDs

Completed· Roche logo

Roche·Phase 3·NCT00810277·14 enrolled

A Study of The Effect of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate on Articular Damage in The Hand in Patients With Moderate to Severe Rheumatoid Arthritis Who Have an Inadequate Response to Non-Biological DMARDs

Withdrawn· Roche logo

Roche·Phase 4·NCT01878318

An Exploratory Study of Tocilizumab in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Current Non-Biologic DMARDs and/or Anti-TNF Therapy.

Completed· Roche logo

Roche·Phase 3·NCT00750880·1,681 enrolled

An Extension to Study MA21573, Evaluating Tocilizumab in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biological DMARDs and/or Anti-tumor Necrosis Factor (TNF) Therapy

Completed· Roche logo

Roche·Phase 3·NCT00883753·934 enrolled

A Study Comparing Infusion Rates of Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis

Completed· Roche logo

Roche·Phase 2·NCT00887341·76 enrolled

A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis

Completed· Roche logo

Roche·Phase 3·NCT00531817·619 enrolled

A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic and/or Biologic DMARDS

Completed· Roche logo

Roche·Phase 4·NCT01149057·145 enrolled

A Long Term Extension Study of WA19926 (NCT01007435) of Tocilizumab (RoActemra/Actemra) in Participants With Early, Moderate to Severe Rheumatoid Arthritis (RA)

Completed· Roche logo

Roche·Phase 3·NCT01668966·23 enrolled

An Efficacy and Safety Study of Subcutaneous Tocilizumab in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Participants With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current Disease-Modifying Antirheumatic Drug (DMARD) Therapy

Completed· Roche logo

Roche·Phase 3·NCT03155347·340 enrolled

A Long-Term Extension Study of WA22762 to Evaluate Safety and Efficacy of Subcutaneous Tocilizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA).

Completed· Roche logo

Roche·Phase 3·NCT01734993·11 enrolled

A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis

Completed· Roche logo

Roche·Phase 3·NCT01007435·1,162 enrolled

Non-Interventional Study of Tocilizumab Subcutaneous (SC) Monotherapy in Participants With Rheumatoid Arthritis (RA)

Completed· Roche logo

Roche··NCT02402686·353 enrolled

A Retrospective Cohort Study on the Risk of Serious Infections in Rheumatoid Arthritis Patients Receiving Tocilizumab

Unknown status·SSungkyunkwan University··NCT04115423·9,508 enrolled

A Study of Tocilizumab in Participants With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Non-Biological Disease-modifying Anti-rheumatic Drugs (DMARDs)

Completed· Roche logo

Roche··NCT01617005·50 enrolled

A Prospective Observational Study of Tocilizumab (RoActemra/Actemra) in Participants With Rheumatoid Arthritis

Completed· Roche logo

Roche··NCT01462162·122 enrolled

A Phase IV Study to Evaluate the Effect of Subcutaneous (SC) Tocilizumab Administered to Participants With Rheumatoid Arthritis (RA) Assessed Using Disease Activity Score (DAS28)

Completed· Roche logo

Roche··NCT02534311·60 enrolled

Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis

Completed· Roche logo

Roche··NCT01579006·184 enrolled

A Time to Cardiovascular Event Analysis Comparing Tocilizumab to Other Biologics in Patients With Rheumatoid Arthritis (RA)

Completed· Roche logo

Roche··NCT02797769·48,950 enrolled

A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent

Completed· Roche logo

Roche·Phase 3·NCT02046603·162 enrolled

Evolution of Adipokines and Body Composition in Rheumatoid Arthritis Patients Receiving Tocilizumab Therapy

Completed·—·Phase 4·NCT02843789·109 enrolled

A Study on Safety and Efficacy of Tocilizumab (RoActemra/Actemra) Alone or in Combination With Non-Biologic Antirheumatics in Participants With Rheumatoid Arthritis

Completed· Roche logo

Roche·Phase 3·NCT01987479·150 enrolled

An Observational Study of Tocilizumab (Actemra) in Participants With Moderate to Severe Rheumatoid Arthritis

Completed· Roche logo

Roche··NCT01741688·16 enrolled

A Non-Interventional Study of Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab) in Monotherapy

Completed· Roche logo

Roche··NCT01705730·71 enrolled

A Non-Interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis

Completed· Roche logo

Roche··NCT01670045·43 enrolled

A Study of Tocilizumab in Combination With Disease-Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Moderate to Severe Active Rheumatoid Arthritis With an Inadequate Response to DMARDs

Completed· Roche logo

Roche·Phase 3·NCT00996606·58 enrolled

Interleukin-6 Inhibitors and Drug-drug Interactions in Patients With Rheumatoid Arthritis

Terminated·UUniversity of Southern Denmark·Phase 1/2·NCT04842981·3 enrolled

A Non-interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis

Completed· Roche logo

Roche··NCT01562327·50 enrolled

A Phase IIb Study for ALX-0061 Monotherapy in Subjects With Rheumatoid Arthritis

Completed·AAblynx, a Sanofi company·Phase 2·NCT02287922·251 enrolled

A Study of the Effects of RoActemra/Actemra on Vaccination in Patients With Rheumatoid Arthritis on Background Methotrexate (VISARA)

Completed· Roche logo

Roche·Phase 4·NCT01163747·91 enrolled

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice

Completed· Roche logo

Roche··NCT01474291·608 enrolled

A Study of Tocilizumab in Combination With an Oral Contraceptive in Patients With Rheumatoid Arthritis

Completed· Roche logo

Roche·Phase 3·NCT01044498·46 enrolled

A Long-Term Extension Study of WA22762 and NA25220 of Subcutaneous (SC) Tocilizumab (TCZ) in Moderate to Severe Rheumatoid Arthritis (RA)

Completed· Roche logo

Roche·Phase 3·NCT01662063·218 enrolled

A Long-Term Extension Study of WA19926 on the Safety of Tocilizumab (RoActemra/Actemra) in Participants With Early Moderate to Severe Rheumatoid Arthritis

Completed· Roche logo

Roche·Phase 3·NCT01655381·15 enrolled

COVID-1919 trials

Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19

Unknown status·TTongji Hospital··NCT04306705·120 enrolled

High-Dose Corticosteroid or Tocilizumab for Clinical Worsening of COVID-19

Withdrawn·MMarmara University·Phase 4·NCT05133635

COVID-19 Study at the Russian Clinical and Research Center of Gerontology of the Pirogov RNRMU

Completed·PPirogov Russian National Research Medical University··NCT05302947·154 enrolled

Show 16 more trials

Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia

Unknown status·—·Phase 3·NCT04361032·260 enrolled

Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)

Terminated·IInsel Gruppe AG, University Hospital Bern·Phase 2·NCT04335071·5 enrolled

Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients

Unknown status·LLisa Barrett·Phase 2·NCT04321993·363 enrolled

Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers

Terminated·BBeneficência Portuguesa de São Paulo·Phase 3·NCT04403685·129 enrolled

Clinical Trial of the Use of Tocilizumab for Treatment of SARS-CoV-2 Infection (COVID-19)

Unknown status·FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau·Phase 2·NCT04332094·276 enrolled

Efficacy of Early Administration of Tocilizumab in COVID-19 Patients

Terminated·AAzienda USL Reggio Emilia - IRCCS·Phase 2·NCT04346355·126 enrolled

Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)

Withdrawn·EEmory University·Phase 3·NCT04361552

Comparison of Tocilizumab Versus Tocilizumab/Infliximab in Patients With COVID-19-associated Cytokine Storm Syndrome

Completed·—··NCT04734678·153 enrolled

Comparative Therapeutic Efficacy and Safety of Different Antiviral and Anti Inflammatory Drugs in COVID-19 Patients.

Unknown status·OOctober 6 University·Phase 4·NCT04779047·150 enrolled

Randomised Evaluation of COVID-19 Therapy

Recruiting·UUniversity of Oxford·Phase 3·NCT04381936·70,000 enrolled

Combination of Inhaled DNase, Baricitinib and Tocilizumab in Severe COVID-19

Unknown status·—·N/A·NCT05279391·150 enrolled

Safety and Effectiveness Study of Tocilizumab in Patients With Severe COVID-19

Unknown status·HHospital Italiano de Buenos Aires··NCT04924829·300 enrolled

Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT04476979·453 enrolled

Tocilizumab Versus Baricitinib in Patients With Severe COVID-19

Completed·UUniversity Hospital of Patras·N/A·NCT05082714·251 enrolled

Low-dose Tocilizumab Versus Standard of Care in Hospitalized Patients With COVID-19

Terminated·UUniversity of Chicago·Phase 2·NCT04479358·85 enrolled

Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis

Unknown status·UUniversità Politecnica delle Marche·Phase 2·NCT04315480·38 enrolled

Tocilizumab11 trials

To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)

Completed· Sanofi logo

Sanofi·Phase 3·NCT01768572·202 enrolled

A Study to Evaluate the Bioequivalence of Tocilizumab Following Subcutaneous Administration Via an Autoinjector (AI 1000-G2) Versus a Pre-Filled Syringe in Healthy Volunteers

Completed· Roche logo

Roche·Phase 1·NCT02678988·189 enrolled

Tocilizumab in Children With ACP

Active, not recruiting·UUniversity of Colorado, Denver·Phase 1·NCT03970226·9 enrolled

Show 8 more trials

A Pharmacodynamic Study to Evaluate Neutrophil Distribution Kinetics and Function Following Single-Dose RoActemra/Actemra (Tocilizumab) in Healthy Volunteers

Completed· Roche logo

Roche·Phase 4·NCT01991990·18 enrolled

RCT of Tocilizumab for Anti-MDA5+DM

Recruiting·PPeking Union Medical College Hospital·N/A·NCT07377058·110 enrolled

Tocilizumab Real-Life Human Factors (RLHFs) Validation Study

Completed· Roche logo

Roche·Phase 4·NCT02682823·91 enrolled

A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT.

Unknown status·YYi Luo·Phase 2·NCT04688021·46 enrolled

Immunoregulatory Mechanisms of Treg Cells Induced by Tocilizumab

Completed·FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau··NCT02963402·35 enrolled

Tocilizumab in Patients With Schnitzler's Syndrome

Completed·KKaroline Krause·Phase 2·NCT03046381·8 enrolled

Tocilizumab and Tofacitinib in the Treatment of Vascular Behçet's Syndrome

Recruiting·PPeking Union Medical College Hospital·Phase 2·NCT05845723·81 enrolled

Treatment of Chronic Active Antibody Mediated Rejection With Tocilizumab

Recruiting·SShahid Beheshti University of Medical Sciences·N/A·NCT07006532·50 enrolled

Pneumonia5 trials

Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)

Unknown status·NNational Cancer Institute, Naples·Phase 2·NCT04317092·402 enrolled

A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia

Completed· Roche logo

Roche·Phase 3·NCT04320615·452 enrolled

Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19

Unknown status·GGrupo de Investigación Clínica en Oncología Radioterapia·N/A·NCT04380818·106 enrolled

Show 2 more trials

A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia

Completed· Roche logo

Roche·Phase 3·NCT04372186·377 enrolled

A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia

Completed· Roche logo

Roche·Phase 3·NCT04409262·649 enrolled

Juvenile Idiopathic Arthritis4 trials

A Study of Subcutaneously (SC) Administered Tocilizumab (TCZ) in Participants With Polyarticular-Course Juvenile Idiopathic Arthritis (pJIA)

Completed· Roche logo

Roche·Phase 1·NCT01904279·52 enrolled

Extension Study Evaluating the Safety and Efficacy of Subcutaneous Tocilizumab (RoActemra/Actemra) Administration in Systemic and Polyarticular-Course Juvenile Idiopathic Arthritis

Completed· Roche logo

Roche·Phase 1·NCT02165345·82 enrolled

A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis Who Completed WA19977 Core Study

Completed· Roche logo

Roche·Phase 3·NCT01667471·6 enrolled

Show 1 more trial

A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis From France Who Completed WA19977 Core Study

Completed· Roche logo

Roche·Phase 3·NCT01673919·7 enrolled

57 more indications

Multiple Myeloma3 trials

Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma

Active, not recruiting·EEmory University·Phase 1·NCT05391750·7 enrolled

Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients

Unknown status·TThe First Affiliated Hospital of Soochow University·Phase 4·NCT05855122·48 enrolled

Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma

Withdrawn·WWashington University School of Medicine·Phase 1·NCT02447055

Takayasu arteritis2 trials

The Registry Study of Takayasu Arteritis in East China

Recruiting·SShanghai Zhongshan Hospital··NCT03893136·1,000 enrolled

A Pilot Study in Severe Patients With Takayasu Arteritis.

Recruiting·SShanghai Zhongshan Hospital·Phase 4·NCT04300686·40 enrolled

Systemic Juvenile Idiopathic Arthritis2 trials

A Study to Evaluate Pharmacokinetics and Safety of Tocilizumab (RoActemra/Actemra) in Participants Less Than 2 Years Old With Active Systemic Juvenile Idiopathic Arthritis (sJIA)

Completed· Roche logo

Roche·Phase 1·NCT01455701·11 enrolled

A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA)

Completed· Roche logo

Roche·Phase 3·NCT00642460·112 enrolled

Interleukin2 trials

Interplay Between Interleukin-6 and Glucagon in the Regulation of Human Amino Acid and Protein Homeostasis

Completed·UUniversity Hospital, Basel, Switzerland·N/A·NCT06721910·26 enrolled

Neutralizing Interleukin (IL)-6

Recruiting·IIcahn School of Medicine at Mount Sinai·Phase 2·NCT07493317·60 enrolled

Polyarticular Juvenile Idiopathic Arthritis2 trials

A Study of Tocilizumab in Patients With Active Polyarticular Juvenile Idiopathic Arthritis

Completed· Roche logo

Roche·Phase 3·NCT00988221·188 enrolled

An Extension Long-Term Study of RoActemra/Actemra (Tocilizumab) in Patients With Polyarticular Juvenile Idiopathic Arthritis Who Completed The WA19977 Study

Completed· Roche logo

Roche·Phase 3·NCT01727986·11 enrolled

Breast Cancer2 trials

Evaluating Tocilizumab for Sever COVID-19 Infection in Breast Cancer vs. Non Cancer Pateints

Completed·—·Phase 2·NCT04871854·100 enrolled

Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 1·NCT03135171·11 enrolled

Methotrexate2 trials

A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX

Completed· Roche logo

Roche·Phase 3·NCT01855789·718 enrolled

Study of the Response and Cardiorespiratory Endurance in Early RA Patients Treated With Tocilizumab or Methotrexate

Completed·PPatrick Durez·N/A·NCT01245452·30 enrolled

Arthritis2 trials

Checkpoint Inhibitor Induced Colitis and Arthritis -Immunomodulation With IL-6 Blockade and Exploration of Disease Mechanisms

Completed·HHerlev Hospital·N/A·NCT03601611·20 enrolled

A Study Assessing the Safety and Efficacy of Subcutaneous RoActemra/Actemra Alone or in Combination With Non-biologic Antirheumatics in Rhuematoid Arthritis Patients in Latin America With Inadequate Response to Non-biologic Antirheumatic Drugs.

Completed· Roche logo

Roche·Phase 3·NCT02011334·285 enrolled

Systemic Sclerosis2 trials

A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis

Completed· Roche logo

Roche·Phase 3·NCT01532869·87 enrolled

A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc)

Completed· Roche logo

Roche·Phase 3·NCT02453256·212 enrolled

Uveitis2 trials

Tocilizumab for the Treatment of Refractory Behcet's Uveitis

Terminated·WWenjie Zheng·Phase 2·NCT03554161·3 enrolled

Study of the Safety, Tolerability, and Bioactivity of Tocilizumab On Patients With Non-infectious UVEITIS: The STOP-UVEITIS Study

Unknown status·UUniversity of Nebraska·Phase 1/2·NCT01717170·36 enrolled

Myasthenia Gravis2 trials

Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia Gravis

Unknown status·TTang-Du Hospital·Phase 2/3·NCT05716035·64 enrolled

Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis

Recruiting·TTang-Du Hospital·Phase 2·NCT05067348·64 enrolled

Dexamethasone2 trials

Interleukin-6 Guided Treatment With Dexamethasone or Tocilizumab in Patients Hospitalized With Acute Respiratory Symptoms - a Feasibility Study

Recruiting·LLorenzo delSorbo·Phase 2·NCT07334379·60 enrolled

Immunomodulatory Effects of Dexamethasone, Tocilizumab and Anakinra During Experimental Human Endotoxemia

Recruiting·RRadboud University Medical Center·Phase 4·NCT06624436·52 enrolled

Locally Advanced2 trials

A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors

Terminated· Roche logo

Roche·Phase 1·NCT03539484·26 enrolled

A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors

Withdrawn· Roche logo

Roche·Phase 1·NCT06372574

Giant Cell Arteritis2 trials

TocilizuMab discontinuAtion in GIant Cell Arteritis

Active, not recruiting·—·Phase 3·NCT06037460·120 enrolled

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab (TCZ) Administered to Participants With Giant Cell Arteritis (GCA).

Completed· Roche logo

Roche·Phase 1·NCT03923738·24 enrolled

Efficacy and Safety2 trials

Efficacy and Safety of Tocilizumab in Adult's Still Disease

Unknown status·TTel-Aviv Sourasky Medical Center·Phase 2·NCT01002781·10 enrolled

The Efficacy and Safety of Tocilizumab for Severe RP-ILD Secondary to Systemic Diseases

Unknown status·PPeking Union Medical College Hospital·Phase 2·NCT05181397·68 enrolled

Polymyalgia Rheumatica2 trials

Safety and Efficacy of tocilizuMAb Versus Placebo in Polymyalgia rHeumatica With glucocORticoid dEpendence SEMAPHORE

Completed·UUniversity Hospital, Brest·Phase 3·NCT02908217·113 enrolled

Lymphocyte and Cytokine Disturbances in Polymyalgia Rheumatica

Completed·UUniversity Hospital, Brest··NCT02888496·40 enrolled

Diffuse Large B-Cell Lymphoma2 trials

A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Completed· Roche logo

Roche·Phase 1·NCT04657302·30 enrolled

A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma

Completed· Roche logo

Roche·Phase 1·NCT04313608·23 enrolled

Hepatocellular Carcinoma2 trials

A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases

Completed· Roche logo

Roche·Phase 1·NCT04338685·55 enrolled

Study of Tocilizumab in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transarterial Chemoembolization (TACE)

Withdrawn·UUniversity of Michigan Rogel Cancer Center·Phase 1/2·NCT02997956

Cytokine Release Syndrome1 trial

Tocilizumab for Cytokine Release Syndrome Prophylaxis in Haploidentical Transplantation

Completed·HHospital Universitario Dr. Jose E. Gonzalez·Phase 1/2·NCT03533101·30 enrolled

Nephrectomy1 trial

Evaluation of the Safety of Use of Anti-IL6 Receptor Antibodies to Reduce Allo-sensitization Post Allograft Nephrectomy

Completed·UUniversity Hospital, Toulouse·Phase 2·NCT04779957·18 enrolled

Schizophrenia1 trial

Tocilizumab in Schizophrenia

Unknown status·BBrian Miller·Phase 1·NCT02874573·20 enrolled

Dermatomyositis1 trial

Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis

Completed·CChester Oddis·Phase 2·NCT02043548·36 enrolled

Systemic Lupus Erythematosus1 trial

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Participants With Systemic Lupus Erythematosus

Completed· Roche logo

Roche·Phase 1·NCT05155345·15 enrolled

Thyroid Associated Ophthalmopathy1 trial

A Study on the Combined Use of Tocilizumab and Flupentixol-Melitracen in the Treatment of Thyroid-Associated Ophthalmopathy

Recruiting·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 4·NCT06927375·60 enrolled

Obesity1 trial

IL-6 Regulation of Substrate Metabolism and Influence of Obesity

Completed·RRigshospitalet, Denmark·N/A·NCT03967691·22 enrolled

Non-ST Elevation Myocardial Infarction1 trial

Effect of the Interleukin-6 Receptor Antagonist Tocilizumab in Non-ST Elevation Myocardial Infarction

Completed·OOslo University Hospital·Phase 2·NCT01491074·120 enrolled

Exercise1 trial

Acute Exercise and NK Cell Regulation in Tissue and Circulation After IL-6R Blockade

Completed·RRigshospitalet, Denmark·N/A·NCT04616235·30 enrolled

Thyroid Eye Disease1 trial

Tocilizumab Treatment in Graves´ Ophthalmopathy (Graves´ Orbitopathy or Thyroid Eye Disease)

Completed·HHospital Clinico Universitario de Santiago·Phase 3·NCT01297699·32 enrolled

Neuromyelitis Optica1 trial

Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders

Completed·TTianjin Medical University General Hospital·Phase 2/3·NCT03350633·118 enrolled

Type 1 Diabetes1 trial

Tocilizumab (TCZ) in New-onset Type 1 Diabetes

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT02293837·136 enrolled

Corticosteroids1 trial

Ultra-short Glucocorticosteroids and Tocilizumab Therapy in GCA Patients

Completed·AAzienda USL Reggio Emilia - IRCCS··NCT05394909·20 enrolled

Thrombocytopenia1 trial

Evaluate the Efficacy and Safety of Various Treatment Schemes for Severe Fever With Thrombocytopenia Syndrome(SFTS)

Unknown status·QQin Ning·Phase 4·NCT05604859·350 enrolled

Atherosclerosis1 trial

Interleukin-6 Receptor Inhibition for Symptomatic Intracranial Atherosclerosis

Not yet recruiting·ZZhujiang Hospital·Phase 3·NCT06447701·486 enrolled

Treatment1 trial

Treatment Tapering in JIA With Inactive Disease

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT02840175·62 enrolled

Pancreatic Cancer1 trial

Ipilimumab, Nivolumab, Tocilizumab and Radiation in Pretreated Patients With Advanced Pancreatic Cancer

Terminated·HHerlev Hospital·Phase 2·NCT04258150·26 enrolled

Fibrosis1 trial

A Prospective Study of Tocilizumab in the Treatment of Idiopathic Retroperitoneal Fibrosis

Unknown status·PPeking Union Medical College Hospital·Phase 4·NCT04762784·40 enrolled

Solid Tumors1 trial

A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors

Terminated· Roche logo

Roche·Phase 1·NCT05129280·23 enrolled

Erdheim-Chester disease1 trial

Pilot Study of Tocilizumab in Patients With Erdheim-Chester Disease

Terminated·OOspedale San Raffaele·Phase 2·NCT01727206·3 enrolled

Chronic Graft Versus Host Disease1 trial

Tocilizumab for Chronic Graft-versus-Host Disease Treatment

Withdrawn·FFred Hutchinson Cancer Center·Phase 2·NCT02174263

Necrosis1 trial

Comparing the Efficacy of Periarticular Bone Structure in Patients Treated With Either Tocilizumab or Tumor Necrosis Factor Blockers

Completed·UUniversity of Erlangen-Nürnberg Medical School··NCT02778789·66 enrolled

Chronic Lymphocytic Leukemia1 trial

A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities

Terminated· Roche logo

Roche·Phase 1·NCT02336048·38 enrolled

Inflammation1 trial

Tocilizumab for Renal Graft Inflammation

Completed·FFlavio Vincenti·Phase 2·NCT02108600·33 enrolled

Baricitinib1 trial

Efficacy of Ramdicivir and Baricitinib for the Treatment of Severe COVID 19 Patients

Unknown status·—·Phase 3·NCT04693026·150 enrolled

Adamantinomatous Craniopharyngioma1 trial

ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma

Recruiting·NNationwide Children's Hospital·Phase 2·NCT05233397·38 enrolled

Cardiac Transplant1 trial

Tocilizumab in Cardiac Transplantation

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT03644667·385 enrolled

Melanoma1 trial

A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas

Completed· Roche logo

Roche·Phase 1·NCT04551352·20 enrolled

Respiratory Failure1 trial

Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection

Terminated·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT04377659·9 enrolled

Behcet's syndrome1 trial

Tocilizumab for the Treatment of Behcet's Syndrome

Terminated·NNYU Langone Health·Phase 2·NCT01693653·1 enrolled

Major Depressive Disorder1 trial

Tocilizumab Augmentation in Treatment-Refractory Major Depressive Disorder

Terminated·—·Phase 2·NCT02660528·3 enrolled

Locally Advanced or Metastatic Solid Tumors1 trial

A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

Terminated· Takeda logo

Takeda·Phase 1/2·NCT05070247·61 enrolled

Metastatic Solid Tumors1 trial

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

Active, not recruiting·UUniversity of Southern California·Phase 1·NCT04616248·14 enrolled

Metastatic Cancer1 trial

Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer

Recruiting·—·Phase 1·NCT06016179·12 enrolled

Transplantation1 trial

Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation

Active, not recruiting·WWeill Medical College of Cornell University·Phase 2·NCT04395222·21 enrolled

Lymphoma1 trial

A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

Completed· Roche logo

Roche·Phase 1·NCT03467373·111 enrolled

Primary Sjögren's Syndrome1 trial

Efficacy of Tocilizumab in Primary Sjögren's Syndrome.

Completed·UUniversity Hospital, Strasbourg, France·Phase 2/3·NCT01782235·110 enrolled

Exercise Training1 trial

Ectopic Adipose Tissue, Exercise Training and IL-6

Completed·RRigshospitalet, Denmark·N/A·NCT02901496·83 enrolled

Unspecified1 trial

Plan Development for Giving Teclistamab in the Outpatient Setting

Recruiting·UUniversity Health Network, Toronto·Phase 4·NCT06251076·15 enrolled

Regulatory

FDA Approval Timeline[5]

Jan 8, 2010

ACTEMRA

BLA BLA125276

Oct 21, 2013

ACTEMRA

BLA BLA125472

Sep 29, 2023

TOFIDENCE

BLA BLA761354

Jan 24, 2025

AVTOZMA

BLA BLA761420

Jan 21, 2026

AVTOZMA

BLA BLA761498

Sources

References

[1]
ClinicalTrials.gov — 449 trial records for Tocilizumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Actemra drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Tocilizumab compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Tocilizumab. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (BLA BLA761498). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Celltrion company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Interleukin-6 Receptor Alpha Subunit Inhibitor[3]
Modality: Monoclonal antibody[3]
Highest Phase: Approved[1]
Company: CCelltrion

Actemra

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q2 2027

Trials by Indication[1]

Rheumatoid Arthritis85 trials

COVID-1919 trials

Tocilizumab11 trials

Pneumonia5 trials

Juvenile Idiopathic Arthritis4 trials

Multiple Myeloma3 trials

Takayasu arteritis2 trials

Systemic Juvenile Idiopathic Arthritis2 trials

Interleukin2 trials

Polyarticular Juvenile Idiopathic Arthritis2 trials

Breast Cancer2 trials

Methotrexate2 trials

Arthritis2 trials

Systemic Sclerosis2 trials

Uveitis2 trials

Myasthenia Gravis2 trials

Dexamethasone2 trials

Locally Advanced2 trials

Giant Cell Arteritis2 trials

Efficacy and Safety2 trials

Polymyalgia Rheumatica2 trials

Diffuse Large B-Cell Lymphoma2 trials

Hepatocellular Carcinoma2 trials

Cytokine Release Syndrome1 trial

Nephrectomy1 trial

Schizophrenia1 trial

Dermatomyositis1 trial

Systemic Lupus Erythematosus1 trial

Thyroid Associated Ophthalmopathy1 trial

Obesity1 trial

Non-ST Elevation Myocardial Infarction1 trial

Exercise1 trial

Thyroid Eye Disease1 trial

Neuromyelitis Optica1 trial

Type 1 Diabetes1 trial

Corticosteroids1 trial

Thrombocytopenia1 trial

Atherosclerosis1 trial

Treatment1 trial

Pancreatic Cancer1 trial

Fibrosis1 trial

Solid Tumors1 trial

Erdheim-Chester disease1 trial

Chronic Graft Versus Host Disease1 trial

Necrosis1 trial

Chronic Lymphocytic Leukemia1 trial

Inflammation1 trial

Baricitinib1 trial

Adamantinomatous Craniopharyngioma1 trial

Cardiac Transplant1 trial

Melanoma1 trial

Respiratory Failure1 trial

Behcet's syndrome1 trial

Major Depressive Disorder1 trial

Locally Advanced or Metastatic Solid Tumors1 trial

Metastatic Solid Tumors1 trial

Metastatic Cancer1 trial

Transplantation1 trial

Lymphoma1 trial

Primary Sjögren's Syndrome1 trial

Exercise Training1 trial

Unspecified1 trial

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Related News